Doxazosin Tablet
Product Images NDC 42291-260

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Doxazosin (NDC 42291-260). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Avkare, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label 2mg 2015 04 09 At 10.41.29 Am

Label for Doxazosin Tablets USP 2 mg by AvKARE, showing a package size of 1000 tablets. The label includes dosing information, storage instructions, and the NDC 42291-258-10. It indicates the product is prescription only and provides patient information instructions.*

FDA Label Image

Label 4mg 2015 04 09 At 10.42.43 Am

Doxazosin 4 mg tablets packaging label by AvKARE. The label shows the proprietary name Doxazosin, dosage strength 4 mg, and the form as tablets USP. It includes the NDC 42291-259-01, a quantity of 100 tablets, and notes Rx only. Additional text instructs pharmacists to dispense the enclosed patient information.*

FDA Label Image

Label 8mg 2015 04 09 At 10.43.48 Am

Doxazosin Tablets, USP 8 mg oral tablets packaging label from AvKARE. The label shows AvKARE logo, product name, strength (8 mg), quantity (100 tablets), National Drug Code (NDC 42291-260-01), and storage instructions. The label instructs dispensing the enclosed patient information leaflet and keeping the product out of children’s reach.*

FDA Label Image

Doxazosin-structure (Doxazosin Structure)

Chemical structure of doxazosin, showing the molecular arrangement including aromatic rings, nitrogen atoms, ether and amine groups, and a sulfonate group, corresponding to the active ingredient doxazosin.*

FDA Label Image

Figure1

Two line graphs showing clinical study results of Doxazosin tablets (up to 8 mg) versus placebo over 14 weeks. The left graph plots mean change in total symptom score from baseline, showing greater symptom improvement for Doxazosin compared to placebo. The right graph plots mean increase in maximum urinary flow rate from baseline, showing higher flow rates with Doxazosin than placebo during the treatment period.*

FDA Label Image

Table3

A data table summarizing effectiveness data from placebo-controlled trials of doxazosin, focusing on symptom score and maximum flow rate changes across three studies with various doses (placebo, 4 mg, and 8 mg). The table provides mean baseline and mean change values for symptom scores and maximum flow rates, along with sample sizes, accompanied by a bar graph illustrating maximum flow rate changes in Study 2.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.